For patients with advanced non-small cell lung cancer (NSCLC), immunotherapeutic approaches are available due to the success of the US Food and Drug Administration (FDA)-approved PD-1/PD-L1 inhibitors pembrolizumab [1], nivolumab [2–5], and atezolizumab [6, 7]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.